Mainline Biosciences (Shanghai) Co., Ltd. – Trademark Portfolio

Entity Type: 16

Mainline Biosciences (Shanghai) Co., Ltd. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include MB and MB MAINLINE BIOSCIENCES. The owner is based in Lingang, Shanghai.

1666 Xinyang Road, Building 2

Lingang, Shanghai 201413 , CN

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Mainline Biosciences (Shanghai) Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Mainline Biosciences (Shanghai) Co., Ltd. have?

Mainline Biosciences (Shanghai) Co., Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.

What trademark classes does Mainline Biosciences (Shanghai) Co., Ltd. file in?

Mainline Biosciences (Shanghai) Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Mainline Biosciences (Shanghai) Co., Ltd.'s most well-known trademarks?

Mainline Biosciences (Shanghai) Co., Ltd.'s registered trademark portfolio includes well-known marks such as MB and MB MAINLINE BIOSCIENCES. These are among 4 currently registered trademarks in the portfolio.

What is Mainline Biosciences (Shanghai) Co., Ltd.'s trademark registration success rate?

Mainline Biosciences (Shanghai) Co., Ltd. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.